When does nitrate tolerance develop? What dosages and which intervals are necessary to ensure maintained effectiveness?
- PMID: 3137072
- DOI: 10.1093/eurheartj/9.suppl_a.63
When does nitrate tolerance develop? What dosages and which intervals are necessary to ensure maintained effectiveness?
Abstract
To address the issues of tolerance development and its circumvention during long-term treatment with nitrates, several controlled studies have been performed. In patients with coronary artery disease, during long-term treatment with isosorbide dinitrate (ISDN) in sustained-release form at dosages of 20 mg t.i.d., 40 mg t.i.d. and 60 mg t.i.d., both the rate of anginal attacks and the ischaemic reaction to exercise were unaffected. After a marked acute anti-ischaemic effect to 40 mg ISDN in nonsustained-release form, during chronic administration of the same dose four times daily, in association with continuously-high nitrate plasma concentrations, similarly, there were no significant effects. On use of nitroglycerin (NTG) transdermal patches delivering 10 mg, 15 mg and 30 mg per 24 hours, respectively, renewed patch application after 24 hours was not met with the same marked response observed after initial application. Clearly attenuated effects could be seen within 8 to 12 hours. These results show that tolerance development is incurred when the incrementation in plasma concentration after a repeated nitrate dose is of relatively limited magnitude with respect to baseline values. The observation of rapid reversibility of nitrate tolerance lead to the concept of interval treatment which on daily use incorporates a sufficiently long period without nitrate administration. On use of a nitrate-free treatment interval employing a regimen of 20 mg ISDN nonsustained-release form twice daily in the morning and at midday, 120 mg ISDN sustained-release form once daily or 50 or 100 mg isosorbide 5-mononitrate once daily, maintained effectiveness has been documented, as it has also been shown for treatment with NTG patches delivering 10 mg per 24 hours on incorporation of a 12-hour patch-free interval. The currently available patch system with discontinuous NTG delivery does not incur a complete loss of action but a considerable attenuation of its effects indicates the need for further refinements. Thus interval treatment guarantees maintenance of nitrate effects, albeit with the limitation that 24-hour therapeutic coverage is not enabled.
Similar articles
-
Short and long-acting oral nitrates for stable angina pectoris.Cardiovasc Drugs Ther. 1994 Aug;8(4):611-23. doi: 10.1007/BF00877415. Cardiovasc Drugs Ther. 1994. PMID: 7848896 Review.
-
Anti-ischaemic response to sublingual nitroglycerin during oral administration of isosorbide dinitrate in patients with stable angina pectoris: when does cross-tolerance occur?Cardiovasc Drugs Ther. 2004 Jan;18(1):47-55. doi: 10.1023/B:CARD.0000025755.94861.dc. Cardiovasc Drugs Ther. 2004. PMID: 15115903 Clinical Trial.
-
Induction and circumvention of nitrate tolerance applying different dosage intervals.Am J Med. 1987 Nov;83(5):860-70. doi: 10.1016/0002-9343(87)90643-7. Am J Med. 1987. PMID: 3674093
-
Effectiveness of interval nitrate therapy in angina pectoris.Eur Heart J. 1989 May;10 Suppl A:50-5. doi: 10.1093/eurheartj/10.suppl_a.50. Eur Heart J. 1989. PMID: 2501095
-
[Avoidance of tolerance development to long term therapy with nitrates through correct dosage].Z Kardiol. 1986;75 Suppl 3:42-9. Z Kardiol. 1986. PMID: 3541418 Review. German.
Cited by
-
Nitric oxide generating/releasing materials.Future Sci OA. 2015;1(1):FSO54. doi: 10.4155/fso.15.54. Future Sci OA. 2015. PMID: 26855790 Free PMC article.
-
Nitrates: why and how should they be used today? Current status of the clinical usefulness of nitroglycerin, isosorbide dinitrate and isosorbide-5-mononitrate.Eur J Clin Pharmacol. 1990;38 Suppl 1:S35-51. doi: 10.1007/BF01417564. Eur J Clin Pharmacol. 1990. PMID: 2113003 Review.
-
Choosing the most appropriate treatment for stable angina. Safety considerations.Drug Saf. 1998 Jul;19(1):23-44. doi: 10.2165/00002018-199819010-00003. Drug Saf. 1998. PMID: 9673856 Review.
-
Pharmacokinetics of oral isosorbide-5-mononitrate in patients with ischemic heart failure.Klin Wochenschr. 1991 Mar 18;69(5):213-9. doi: 10.1007/BF01646943. Klin Wochenschr. 1991. PMID: 2033915
-
Nitrate tolerance. A review of the evidence.Drugs. 1989 Apr;37(4):523-50. doi: 10.2165/00003495-198937040-00006. Drugs. 1989. PMID: 2661197 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous